Press Releases

Date Title  
Jan 23, 2020
CAMBRIDGE, Mass. , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone , M.D., M.S.C.E., to its
Jan 9, 2020
CAMBRIDGE, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray , Ph.D., chief executive officer and